TACSTD2 and cancer: Given that tumor-specific cleavage induced by ADAM10 triggers the conformational rearrangement of Trop2-ECD and might expose previously inaccessible sites, Alberti and colleagues recently used deletion mutagenesis without immunodominant epitopes to generate a cancer-specific CPD-targeted mAb 2G10 (58).